Daunomycin

Myelodysplastic Syndrome

OHSU Knight Cancer InstituteSmall moleculePhase 3Active

BB

70/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 72/ 100
Competitive Position: 65/ 100

Competitive context

295 Active assets in the Myelodysplastic Syndrome cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Sawa Ito, MD	Phase 4	BB
Nivestim City of Hope Medical Center	Phase 4	BB
BUSULFANUM Sawa Ito, MD	Phase 4	BB
CYTARABINE The First Affiliated Hospital of Soochow University	Phase 4	BB
Fludarabine City of Hope Medical Center	Phase 4	BB

View all 50 →

Same molecule, other indications

Daunomycin is also rated in:

acute myeloid leukemia by FAB classificationActive

BBB

Indicative · Phase 3

78 / 100

acute myeloid leukemia with 11q23 abnormalitiesActive

BBB

Indicative · Phase 3

77 / 100

acute monocytic leukemiaActive

BBB

Indicative · Phase 3

77 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.